Valemetostat tosylate DS-3201 tosylate|cas:1809336-93-3|西域试剂

Valemetostat tosylate DS-3201 tosylate,98.14%

产品编号：Bellancom-109108A| CAS NO：1809336-93-3| 分子式：C₃₃H₄₂ClN₃O₇S| 分子量：660.22

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-109108A	￥2500.00	杭州北京（现货）
Bellancom-109108A	￥4200.00	杭州北京（现货）
Bellancom-109108A	￥8800.00	杭州北京（现货）
Bellancom-109108A	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Valemetostat tosylate DS-3201 tosylate

产品介绍

Valemetostat tosylate (DS-3201 tosylate) 是一种首创的 EZH1/2 抑制剂，IC₅₀ 值＜10 nM。Valemetostat tosylate 可用于复发以及难治型周围 T 细胞淋巴瘤的研究。

生物活性

Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma.

体外研究

Valemetostat tosylate (1-1000 nM) strongly and specifically inhibits EZH1 and EZH2 with IC₅₀ values ＜10 nM.
Valemetostat tosylate (100 nM; 7 d) effectively removes H3K27me3 and also prevents unexpected gain of H3K27me3.
Valemetostat tosylate (0.1-100 nM; 7 d) potently inhibits H3K27me3 by low-dose treatment in the sensitive lymphoma types.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Valemetostat tosylate (0.01 mg/g; i.p.; once) prevents the changes of H3K27me3 after exercise training.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice with chronic and acute running exercise or without exercise
Dosage:	0.01 mg/g
Administration:	Intraperitoneal injection; 0.01 mg/g; 30 min before the start of running exercise
Result:	Significantly increased the level of H3K27me3 , slightly decresed EZH1 level , upregulated the EZH2 level and increased the level of phosphorylated AMPK after exercise. Repressed myonuclear H3K27me3 accumulation during training and caused a failure of adaptive changes.

体内研究

Valemetostat tosylate (0.01 mg/g; i.p.; once) prevents the changes of H3K27me3 after exercise training.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice with chronic and acute running exercise or without exercise
Dosage:	0.01 mg/g
Administration:	Intraperitoneal injection; 0.01 mg/g; 30 min before the start of running exercise
Result:	Significantly increased the level of H3K27me3 , slightly decresed EZH1 level , upregulated the EZH2 level and increased the level of phosphorylated AMPK after exercise. Repressed myonuclear H3K27me3 accumulation during training and caused a failure of adaptive changes.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (151.46 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5146 mL	7.5732 mL	15.1465 mL
5 mM	0.3029 mL	1.5146 mL	3.0293 mL
10 mM	0.1515 mL	0.7573 mL	1.5146 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.15 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.15 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.15 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.15 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.15 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.15 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。